Michael Gray
Director Financiero/CFO en Carmot Therapeutics, Inc. .
Fortuna: 115 832 $ al 30/04/2024
Cargos activos de Michael Gray
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
The American Institute of Certified Public Accountants
 The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Corporate Officer/Principal | - | - |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Director de Operaciones | 06/06/2023 | - |
| Director Financiero/CFO | 06/06/2023 | - |
Historial de carrera de Michael Gray
Antiguos cargos conocidos de Michael Gray.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ENLIVEN THERAPEUTICS, INC. | Director de Operaciones | 26/02/2019 | 23/02/2023 |
| Director Financiero/CFO | 26/02/2019 | 23/02/2023 | |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Director/Miembro de la Junta | 27/11/2018 | 13/03/2019 |
| Director Ejecutivo | 27/11/2018 | 13/03/2019 | |
| Director de Operaciones | 01/09/2017 | - | |
| Director Financiero/CFO | 02/03/2016 | 13/03/2019 | |
| Contacto de Relaciones con Inversores | 02/03/2016 | 13/03/2019 | |
| Presidente | 27/11/2018 | 13/03/2019 | |
| X4 PHARMACEUTICALS, INC. | Director Ejecutivo | 01/11/2018 | 13/03/2019 |
| Director Financiero/CFO | 01/03/2016 | 13/03/2019 | |
| Presidente | 01/11/2018 | 13/03/2019 | |
| CURIS, INC. | Director Financiero/CFO | 01/08/2000 | 29/02/2016 |
| Public Communications Contact | 01/08/2000 | 29/02/2016 | |
| Secretario Corporativo | 01/08/2000 | 29/02/2016 | |
| Treasurer | 01/08/2000 | - | |
Reprogenesis, Inc.
 Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Comptroller/Controller/Auditor | 01/01/1998 | 01/07/2000 |
| TETRAPHASE PHARMACEUTICALS, INC. | Director Financiero/CFO | - | - |
| THES ACQU | Director/Miembro de la Junta | 01/05/2020 | - |
| Independent Dir/Board Member | 01/05/2020 | - | |
| ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ | - | |
| ░░░░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | - |
Formación de Michael Gray.
| Bryant University | Undergraduate Degree |
| F.W. Olin Graduate School of Business | Masters Business Admin |
Estadísticas
Internacional
| Estados Unidos | 13 |
Operativa
| Director of Finance/CFO | 7 |
| Chief Operating Officer | 4 |
| Director/Board Member | 2 |
Sectorial
| Health Technology | 9 |
| Consumer Services | 3 |
| Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| CURIS, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| ENLIVEN THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 7 |
|---|---|
Reprogenesis, Inc.
Reprogenesis, Inc. BiotechnologyHealth Technology Reprogenesis, Inc., located in Cambridge, Massachusetts developes tissue engineered therapies to treat unmet medical needs. The Company has proprietary technology utilizing the combination of cells and biomaterials to restore, repair or replace lost tissue or physiological function. The Company has a broad preclinical and clinical pipeline of products in the areas of urology, cardiovascular biology and plastic and reconstructive surgery. ChondrogelTM is its most advanced product | Health Technology |
Arsanis, Inc.
Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
Imara, Inc.
 Imara, Inc. Pharmaceuticals: MajorHealth Technology Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA. | Health Technology |
The American Institute of Certified Public Accountants
The American Institute of Certified Public Accountants Miscellaneous Commercial ServicesCommercial Services The American Institute of Certified Public Accountants provides vocational education in accounting. The company provides services to the accounting community, regulatory bodies, and other organizations. It also operates in Jersey City, Washington, and Lewisville. It was founded in 1887 and is headquartered in New York City, NY. | Commercial Services |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA. | Finance |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tetraphase Pharmaceuticals, Inc. is engaged in the development and production of novel tetracyclines for serious and life-threatening bacterial infections. It also develops eravacycline, a synthetic fluorocycline, as an intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of resistant and multi-drug-resistant infections. The company was founded on July 7, 2006 and is headquartered in Waltham, MA. | Health Technology |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Michael Gray
- Experiencia
